<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04336566</url>
  </required_header>
  <id_info>
    <org_study_id>10584</org_study_id>
    <nct_id>NCT04336566</nct_id>
  </id_info>
  <brief_title>Renal Effects of Melatonin Trial in Chronic Kidney Disease</brief_title>
  <acronym>REM</acronym>
  <official_title>Renal Function in Chronic Kidney Disease and the Effect of Exogenous Melatonin Administration (REM TRIAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a prospective, double blinded, randomized, controlled pilot study to determine
      if there is any correlation between melatonin administration and proteinuria.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators plan to enroll up to 100 eligible participants in this pilot trial with 50
      participants randomized to receive melatonin and 50 patients randomized to receive a placebo.
      Participants will be randomized on a rolling basis; meaning, once participants agree to
      enroll in the study, the participant will be placed randomly into either group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Actual">May 13, 2020</completion_date>
  <primary_completion_date type="Actual">May 13, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participant, care provider, data manager/monitor, principle investigator all blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Albuminuria</measure>
    <time_frame>6 months</time_frame>
    <description>protein in urine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surveys including Pittsburgh Sleep Quality Index (PSQI) questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Scale 0-21, higher scores indicate worse sleep quality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sodium levels</measure>
    <time_frame>6 months</time_frame>
    <description>electrolyte in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis</measure>
    <time_frame>6 months</time_frame>
    <description>To asses electrolyte and protein levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine levels</measure>
    <time_frame>6 months</time_frame>
    <description>serum blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Urea Nitrogen (BUN) levels</measure>
    <time_frame>6 months</time_frame>
    <description>Blood Urea Nitrogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potassium levels</measure>
    <time_frame>6 months</time_frame>
    <description>mineral in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bicarbonate levels</measure>
    <time_frame>6 months</time_frame>
    <description>base found in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chloride levels</measure>
    <time_frame>6 months</time_frame>
    <description>electrolyte in blood</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5mg dose of melatonin manufactured by Good Neighbor Pharmacy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Good Neighbor Pharmacy placebo tablet that looks the same without active ingredient</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>Melatonin 5mg</description>
    <arm_group_label>Melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Comparable Good Neighbor Pharmacy placebo tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are between ages 18-85 with chronic kidney disease (CKD) I-III (stage 3 kidney
             disease, kidney dysfunction)

          -  Random urine microalbumin of 30 mcg or greater (protein in the urine)

          -  Have ability to complete a sleep survey

          -  Currently not on melatonin therapy.

        Exclusion Criteria:

          -  End Stage Renal Disease

          -  CKD Stage IV (stage 4 with severe kidney dysfunction)

          -  Severe liver disease

          -  Chronic dialysis therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Krishna M Baradhi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OUHSC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Oklahoma School of Community Medicine</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Kidney Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

